Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
AIDS Research and Human Retroviruses|September 20, 2021
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil FumarateIan M McGowan, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2022
MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine GelKen Ho, Clara Dominguez-Islas, Daniel Szydlo, et al.
Plos One|July 1, 2016
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender WomenIan McGowan, Ross D Cranston, Kenneth H Mayer, et al.
The Journal of Infectious Diseases|April 24, 2024
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV PreventionSharon A Riddler, Clifton W Kelly, Craig J Hoesley, et al.
AIDS (London, England)|December 18, 2018
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSMIan McGowan, Timothy Wilkin, Raphael J Landovitz, et al.
Science Translational Medicine|December 6, 2019
The human tissue-resident CCR5<sup>+</sup> T cell compartment maintains protective and functional properties during inflammationAmanda S Woodward Davis, Hayley N Roozen, Matthew J Dufort, et al.
AIDS (London, England)|April 8, 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxisRogers Sekabira, Ian McGowan, Krista Yuhas, et al.
The Lancet. HIV|September 24, 2016
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessmentIan McGowan, Charlene S Dezzutti, Aaron Siegel, et al.
AIDS Research and Human Retroviruses|August 13, 2021
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)Ian M McGowan, Sylvain Chawki, Craig W Hendrix, et al.
AIDS Research and Human Retroviruses|September 9, 2021
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026)Ross D Cranston, Elizabeth Brown, José Bauermeister, et al.
Pageof 6